Specialist Updates 
Oncology

Setback for improved therapy in advanced urothelial cancer

Neither mono nor dual immune checkpoint inhibitor therapy improved survival in multi-nation study
Medicom Staff writer
0
25 September 2020
Save
ClosePlease login

AusDoc brings you the latest news from the European Society for Medical Oncology virtual congress 2020.

A bid to harness immune checkpoint blockade to improve first-line therapy for patients with untreated metastatic urothelial cancer has faltered with a phase 3 trial failing to meet primary endpoints, a conference has heard.

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Content that breaches the privacy of other individuals
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .